NME2 and squamous cell carcinoma: This result was further supported by IHC analysis of NME2 in primary lung tumors and matched lymph node metastases from same patients (n = 100; adenocarcinoma as well as squamous cell carcinoma) where we found reduced NME2 level in metastases compared to primary tumors (Figure 2C).